<- Go Home
Eterna Therapeutics Inc.
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Market Cap
$26.4M
Volume
19.0K
Cash and Equivalents
$4.3M
EBITDA
-$20.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$436.0K
Profit Margin
72.91%
52 Week High
$2.63
52 Week Low
$0.49
Dividend
N/A
Price / Book Value
-0.06
Price / Earnings
-0.06
Price / Tangible Book Value
-0.06
Enterprise Value
$59.8M
Enterprise Value / EBITDA
-4.52
Operating Income
-$20.3M
Return on Equity
214.83%
Return on Assets
-42.35
Cash and Short Term Investments
$4.3M
Debt
$37.7M
Equity
-$45.4M
Revenue
$598.0K
Unlevered FCF
-$11.4M
Sector
Biotechnology
Category
N/A